174 Les biomarqueurs moléculaires en oncologie
16. Xie J, Chen K, Huang J, et al. (2010). PET/NIRF/MRI triple functional iron oxide
l l
nanoparticles. Biomaterials 31: 3016-22
17. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ (2009) Pre-clinical PET/MR: technological
advances and new perTEMPives in biomedical research. Eur J Nucl Med Mol Imaging 36
Suppl 1: S56-68
18. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):
646-74
19. Shields AF (2012) PET imaging of tumor growth: not as easy as it looks. Clin Cancer Res
18(5): 1189-91
20. Yang TJ, Haimovitz-Friedman A, Verheij M (2012). Anticancer therapy and apoptosis
imaging. Exp Oncol 34(3): 269-76
21. Gaertner FC, Kessler H, Wester HJ, et al. (2012). Radiolabelled RGD peptides for imaging
l l
and therapy. Eur J Nucl Med Mol Imaging 39 Suppl 1: S126-38
22. Michalski MH, Chen X (2011) Molecular imaging in cancer treatment. Eur J Nucl Med
Mol Imaging 38(2): 358-77
23. Lee CM, Jang D, Cheong SJ, et al. (2012) Optical imaging of MMP expression and cancer
l l
progression in an inflammation-induced colon cancer model. Int J Cancer 131(8): 1846-53
24. Toyohara J, Ishiwata K (2011) Animal tumor models for PET in drug development. Ann
Nucl Med 25(10): 717-31
25. Herholz K, Langen KJ, Schiepers C, Mountz JM (2012) Brain tumors. Semin Nucl Med
42(6): 356-70
26. Soyka JD, Muster MA, Schmid DT, et al. l l (2012) Clinical impact of 18F-choline PET/CT
in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 39(6): 936-43
27. Moreau M, Raguin O, Vrigneaud JM, et al. (2012) DOTAGA-Trastuzumab a new
l l
antibody conjugate targeting HER2/Neu antigen for diagnostic purposes. Bioconjugate
Chem 23(6): 1181-8
28. Vandsburger MH, Radoul M, Cohen B, Neeman M (2013) MRI reporter genes:
applications for imaging of cell survival, proliferation, migration and differentiation. NMR
Biomed 26(7): 872-84
29. Ottobrini L, Martelli C, Trabattoni DL, et al. l l (2011) In vivo imaging of immune cell
trafficking in cancer. Eur J Nucl Med Mol Imaging 38(5): 949-68
30. Groheux D, Hindie E, Delord M, et al. (2012) Prognostic Impact of 18FDG-PET-CT
l l
Findings in Clinical Stage III and IIB Breast Cancer. J Natl Cancer Inst 104(24): 1879-87
31. Pan L, Han Y, Sun Xe, et al. (2010) FDG-PET and other imaging modalities for the
l l
evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin
Oncol 136(7): 1007-22
32. Rousseau C, Devillers A, Sagan C, et al. (2006) Monitoring of early response to
l l
neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose
positron emission tomography. J Clin Oncol 24(34): 5366-72
33. Cachin F, Prince HM, Hogg A, et al. (2006) Powerful prognostic stratification by [18F]
fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer
treated with high-dose chemotherapy. J Clin Oncol 24(19): 3026-31
34. Humbert O, Berriolo-Riedinger A, Riedinger, et al. (2012) Changes in 18F-FDG tumor
metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of
tumor subtypes. Ann Oncol 23(10): 2572-7
35. Kenny LM, Contractor KB, Hinz R, et al. (2010) Reproducibility of [11C]choline-positron
l l
emission tomography and effect of trastuzumab. Clin Cancer Res 16(16): 4236-45
36. Contractor KB, Kenny LM, Stebbing J, et al. (2011) [18F]-3’Deoxy-3’-fluorothymidine
positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res
17(24): 7664-72
37. Chung SH, Yu H, Su MY, et al. (2012) Molecular imaging of water binding state and
l l
diffusion in breast cancer using diffuse optical spectroscopy and diffusion weighted MRI.
J Biomed Opt 17(7): 071304
16. Xie J, Chen K, Huang J, et al. (2010). PET/NIRF/MRI triple functional iron oxide
l l
nanoparticles. Biomaterials 31: 3016-22
17. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ (2009) Pre-clinical PET/MR: technological
advances and new perTEMPives in biomedical research. Eur J Nucl Med Mol Imaging 36
Suppl 1: S56-68
18. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):
646-74
19. Shields AF (2012) PET imaging of tumor growth: not as easy as it looks. Clin Cancer Res
18(5): 1189-91
20. Yang TJ, Haimovitz-Friedman A, Verheij M (2012). Anticancer therapy and apoptosis
imaging. Exp Oncol 34(3): 269-76
21. Gaertner FC, Kessler H, Wester HJ, et al. (2012). Radiolabelled RGD peptides for imaging
l l
and therapy. Eur J Nucl Med Mol Imaging 39 Suppl 1: S126-38
22. Michalski MH, Chen X (2011) Molecular imaging in cancer treatment. Eur J Nucl Med
Mol Imaging 38(2): 358-77
23. Lee CM, Jang D, Cheong SJ, et al. (2012) Optical imaging of MMP expression and cancer
l l
progression in an inflammation-induced colon cancer model. Int J Cancer 131(8): 1846-53
24. Toyohara J, Ishiwata K (2011) Animal tumor models for PET in drug development. Ann
Nucl Med 25(10): 717-31
25. Herholz K, Langen KJ, Schiepers C, Mountz JM (2012) Brain tumors. Semin Nucl Med
42(6): 356-70
26. Soyka JD, Muster MA, Schmid DT, et al. l l (2012) Clinical impact of 18F-choline PET/CT
in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 39(6): 936-43
27. Moreau M, Raguin O, Vrigneaud JM, et al. (2012) DOTAGA-Trastuzumab a new
l l
antibody conjugate targeting HER2/Neu antigen for diagnostic purposes. Bioconjugate
Chem 23(6): 1181-8
28. Vandsburger MH, Radoul M, Cohen B, Neeman M (2013) MRI reporter genes:
applications for imaging of cell survival, proliferation, migration and differentiation. NMR
Biomed 26(7): 872-84
29. Ottobrini L, Martelli C, Trabattoni DL, et al. l l (2011) In vivo imaging of immune cell
trafficking in cancer. Eur J Nucl Med Mol Imaging 38(5): 949-68
30. Groheux D, Hindie E, Delord M, et al. (2012) Prognostic Impact of 18FDG-PET-CT
l l
Findings in Clinical Stage III and IIB Breast Cancer. J Natl Cancer Inst 104(24): 1879-87
31. Pan L, Han Y, Sun Xe, et al. (2010) FDG-PET and other imaging modalities for the
l l
evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin
Oncol 136(7): 1007-22
32. Rousseau C, Devillers A, Sagan C, et al. (2006) Monitoring of early response to
l l
neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose
positron emission tomography. J Clin Oncol 24(34): 5366-72
33. Cachin F, Prince HM, Hogg A, et al. (2006) Powerful prognostic stratification by [18F]
fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer
treated with high-dose chemotherapy. J Clin Oncol 24(19): 3026-31
34. Humbert O, Berriolo-Riedinger A, Riedinger, et al. (2012) Changes in 18F-FDG tumor
metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of
tumor subtypes. Ann Oncol 23(10): 2572-7
35. Kenny LM, Contractor KB, Hinz R, et al. (2010) Reproducibility of [11C]choline-positron
l l
emission tomography and effect of trastuzumab. Clin Cancer Res 16(16): 4236-45
36. Contractor KB, Kenny LM, Stebbing J, et al. (2011) [18F]-3’Deoxy-3’-fluorothymidine
positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res
17(24): 7664-72
37. Chung SH, Yu H, Su MY, et al. (2012) Molecular imaging of water binding state and
l l
diffusion in breast cancer using diffuse optical spectroscopy and diffusion weighted MRI.
J Biomed Opt 17(7): 071304